CD8A and neoplasm: In a recent publication using a mouse methylcholanthrene-induced sarcoma model, in which the mutations recognized by CD4+ and CD8+ T cells were distinct (17), coexpression of those mutations in the same tumor cells was required for tumor rejection by immunotherapy.